Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines.

por Klaassen, U., Harstrick, A., Schleucher, N., Vanhoefer, U., Schröder, J., Wilke, H., Seeber, S.
Publicado 1996

Moderately degenerated lumbar motion segments: Are they truly unstable?

por van Rijsbergen, M. M., Barthelemy, V. M. P., Vrancken, A. C. T., Crijns, S. P. M., Wilke, H.-J., Wilson, W., van Rietbergen, B., Ito, K.
Publicado 2016

Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II tria...

por Eberhardt, W, Stamatis, G, Stuschke, M, Wilke, H, Müller, M R, Kolks, S, Flasshove, M, Schütte, J, Stahl, M, Schlenger, L, Budach, V, Greschuchna, D, Stüben, G, Teschler, H, Sack, H, Seeber, S
Publicado 1999

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated ga...

por Al-Batran, S.-E., Van Cutsem, E., Oh, S. C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O. N., Kim, T.-Y., Cunningham, D., Rougier, P., Muro, K., Liepa, A. M., Chandrawansa, K., Emig, M., Ohtsu, A., Wilke, H.
Publicado 2016

Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial

por Köhne, C-H, Catane, R, Klein, B, Ducreux, M, Thuss-Patience, P, Niederle, N, Gips, M, Preusser, P, Knuth, A, Clemens, M, Bugat, R, Figer, I, Shani, A, Fages, B, Betta, D Di, Jacques, C, Wilke, H J
Publicado 2003